Is it time to reconsider combination lipid therapy in high-risk diabetic patients?

Curr Opin Lipidol. 2016 Jun;27(3):310-1. doi: 10.1097/MOL.0000000000000306.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / metabolism
  • Diabetes Complications* / drug therapy
  • Diabetes Complications* / metabolism
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Lipid Metabolism / drug effects*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors